Cytek Biosciences/$CTKB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
- Ticker
- $CTKB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 682
- Headquarters
- Fremont, United States
- Website
- cytekbio.com
CTKB Metrics
BasicAdvanced
$706M
-
-$0.63
1.14
-
Price and volume
Market cap
$706M
Beta
1.14
52-week high
$6.34
52-week low
$3.31
Average daily volume
1.4M
Financial strength
Current ratio
4.46
Quick ratio
3.709
Long term debt to equity
0.04
Total debt to equity
0.04
Interest coverage (TTM)
-571.68%
Profitability
EBITDA (TTM)
-36.668
Gross margin (TTM)
54.75%
Net profit margin (TTM)
-39.10%
Operating margin (TTM)
-21.47%
Effective tax rate (TTM)
-103.22%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-5.92%
Return on equity (TTM)
-23.20%
Valuation
Price to revenue (TTM)
3.359
Price to book
2.2
Price to tangible book (TTM)
2.43
Growth
Revenue change (TTM)
5.50%
Earnings per share change (TTM)
484.39%
3-year revenue growth (CAGR)
4.28%
3-year earnings per share growth (CAGR)
81.31%
What the Analysts think about CTKB
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
Analyst projections of the future price of Cytek Biosciences stock.
Bulls say / Bears say
Cytek is extending its software ecosystem with Cloud Analysis and a new paid Premium tier, building on more than 28,000 users. If customers adopt the new tools, the platform could deepen engagement and add subscription revenue. (Cytek Biosciences)
A collaboration with Sysmex Europe gives Cytek access to clinical laboratories in more than a dozen countries and pairs its spectral cytometer with Sysmex’s established workflow products. This could widen its reach in specialised diagnostic testing beyond research labs. (Sysmex Europe)
Recurring service and reagent sales rose to 35% of trailing-year revenue from 32% a year earlier, while the installed base grew to 3,933 instruments. A larger base gives Cytek more scope to grow repeat sales alongside instrument placements. (Cytek Biosciences)
A US jury found that Cytek products infringed a Beckman Coulter patent and awarded $56 million in royalties and lost profits. The award creates a material financial risk while Cytek pursues post-trial remedies. (Reuters)
Operating expenses rose 15% in the second quarter, and Cytek’s net loss widened to $12.2 million from $5.6 million a year earlier. The company remains loss-making despite revenue growth, leaving execution on costs important to the investment case. (Cytek Biosciences)
The recovery remains uneven: Europe continued to face government budget pressure, while sales outside China were soft in parts of Asia-Pacific. This leaves Cytek exposed if strength in the US and China does not broaden to other markets. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
CTKB Financial Performance
Revenues and expenses
CTKB Earnings Performance
Company profitability
Upcoming events
No upcoming events
CTKB News
AllArticlesVideos
Funds containing CTKB
Fund name | Fund size | $CTKB weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.07% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.07% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.